Generic Product News

Pharmacy TimesMarch 2013 Central Nervous System
Volume 79
Issue 3

New generic products for male pattern hair loss, cholesterol reduction, serious infections, and dermatoses of the scalp

Finasteride Tablets

Marketed by: Dr. Reddy’s Laboratories

Compare to: Propecia (Merck & Co, Inc)

Indication: Finasteride Tablets are a bioequivalent generic version of Propecia. They are indicated for the treatment of male pattern hair loss in men only. They are not indicated for use in women. The recommended dose is 1 tablet once daily with or without meals. In general, daily use for 3 months or more is necessary before benefit is observed. Finasteride Tablets are available in bottle counts of 30 and 90.

Dosage Form: Tablets: 1 mg

For More Information:

Fenofibrate Tablets

Marketed by: Teva Pharmaceuticals

Compare To: TriCor (Abbott Laboratories)

Indication: Teva Pharmaceuticals offers fenofibrate tablets, the authorized generic version of Abbott Laboratories’ TriCor tablets. Fenofibrate tablets are indicated to decrease low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia. The tablets are also indicated for treatment of adult patients with severe hypertriglyceridemia. They may be taken without regard to meals.

Dosage Form: Tablets: 48 mg or 145 mg

For More Information:

Clindamycin in 5% Dextrose

Marketed by: Sandoz Inc

Compare to: Cleocin Phosphate in Dextrose 5% (Pfizer Inc)

Indication: Clindamycin in 5% dextrose is an antibiotic indicated for the treatment of serious infections caused by susceptible anaerobic bacteria. It is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. It should be reserved for use in penicillin-allergic patients or in patients for whom penicillin use is deemed inappropriate.

Dosage Form: Minibags: 300 mg/50 ml; 600 mg/50 ml; 900mg/50 ml

For More Information:

Clobetasol Emulsion Propionate Foam, 0.05%

Marketed by: Perrigo Company

Compare to: Olux-E Foam, 0.05% (GlaxoSmithKline)

Indication: Clobetasol emulsion propionate foam, 0.05% (emollient formulation) is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroidresponsive dermatoses of the scalp in patients 12 years or older. Patients should apply a thin layer of foam to the affected areas twice daily in the morning and evening for up to 2 weeks. Therapy should be discontinued once control has been achieved.

Dosage Form: Foam: 50 g; 100 g

For More Information:

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.